(IN BRIEF) Basilea Pharmaceutica Ltd has received an additional USD 5.4 million from BARDA to continue development of its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil. The antibiotic is being developed for complicated urinary tract infections, including pyelonephritis, particularly infections caused by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Investment, Pharma & Biotech, Science, Switzerland, Technology
Tagged Additional BARDA Support Brings Basilea Funding for Ceftibuten-Ledaborbactam to USD 30.8 Million, Administration for Strategic Preparedness and Response, Allschwil, anti-infectives, antimicrobial resistance, ASPR, BARDA, BARDA Awards Further Funding to Basilea for Ceftibuten-Ledaborbactam Development, Basilea, Basilea Advances Oral Antibiotic Candidate for Complicated Urinary Tract Infections, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, beta lactam beta lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI, boronic acid beta-lactamase inhibitor, BSLN, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, Cresemba®, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, fungal infections, Gram-negative bacteria, investigational drug, KPC, ledaborbactam, ledaborbactam etzadroxil, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, oral cephalosporin, OXA-48, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, Severe Bacterial Infections, SIX Swiss Exchange, Switzerland, U.S Department of Health and Human Services, U.S. FDA, USD 172 million contract potential, USD 30.8 million total funding, USD 5.4 million funding, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has received an additional USD 30 million from BARDA to support the ongoing phase 3 development of fosmanogepix, its novel first-in-class broad-spectrum antifungal candidate. The funding was awarded after Basilea met a prespecified enrolment milestone and … Read the full press release
Posted in Business, Financial, Government, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Administration for Strategic Preparedness and Response, agreement number 75A50124C00033, Allschwil, antifungal treatment, aspergillosis, Aspergillus, ASPR, azole-resistant strains, BAL2062, BARDA, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, Basilea Secures New BARDA Tranche After Phase 3 Enrolment Milestone, Basilea Strengthens Antifungal Pipeline Funding Under Existing BARDA Agreement, Biomedical Advanced Research and Development Authority, broad-spectrum antifungal, Candida glabrata, Candida auris, candidemia, candidiasis, David Veitch, FAST study, Fast Track Designation, FDA, first in class antifungal, FORWARD study, fosmanogepix, Fosmanogepix Development Advances With Additional USD 30 Million BARDA Support, Fusarium, HHS, immunocompromised patients, invasive aspergillosis, invasive candidiasis, invasive fungal infections, Mucorales, multidrug-resistant fungal infections, orphan drug designation, OTA, Other Transaction Agreement, Phase 3 development, QIDP, Qualified Infectious Disease Product, Scedosporium, Switzerland, U.S Department of Health and Human Services, U.S. Food and Drug Administration, United States, USD 268 million potential non-dilutive funding, USD 30 million funding, USD 93 million committed funding
(IN BRIEF) Basilea Pharmaceutica has received an additional USD 13.3 million from BARDA to continue development of ceftibuten-ledaborbactam etzadroxil, an investigational oral beta-lactam/beta-lactamase inhibitor antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The latest tranche brings BARDA’s total … Read the full press release
Posted in Business, Economy, Financial, Government, Healthcare, Industrial, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology, Transportation & Logistics
Tagged Administration for Strategic Preparedness and Response, Allschwil, antibiotic resistance, antimicrobial resistance, ASPR, BARDA, BARDA Funding Supports Basilea’s Efforts to Address Unmet Need in Oral Treatment of Complicated Urinary Tract Infections, Basilea, Basilea Pharmaceutica Ltd, Basilea Receives Additional USD 13.3 Million BARDA Funding to Advance Novel Oral Antibiotic Development, Basilea Secures Additional Non-Dilutive Funding to Prepare Ceftibuten-Ledaborbactam for Phase 3 Development, Basilea Secures Additional USD 13.3 Million BARDA Funding to Advance Development of Novel Oral Antibiotic Ceftibuten-Ledaborbactam, beta-lactam, beta-lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI combination, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, Gram-negative bacteria, infectious diseases, KPC, ledaborbactam etzadroxil, MDR Enterobacterales, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, OXA-48, phase 3 programme, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, SIX: BSLN, Switzerland, U.S Department of Health and Human Services, U.S. FDA
(IN BRIEF) Evotec SE’s subsidiary Just – Evotec Biologics has been selected by the Biomedical Advanced Research and Development Authority BioMaP Consortium to support a multi-year initiative aimed at improving manufacturing processes for antibody-based treatments targeting Ebola and Sudan virus. … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged antibody development, ASPR, BARDA, biologics manufacturing, BioMaP Consortium, Ebola virus, Evotec SE, Evotec Strengthens Biomanufacturing Capabilities Through U.S.-Backed Program Targeting Emerging Viral Outbreaks, filovirus infections, global health security, Just – Evotec Biologics, monoclonal antibody therapy, outbreak preparedness, scalable production, Sudan virus, U.S Department of Health and Human Services
Ad hoc announcement pursuant to Art. 53 LR (IN BRIEF) Basilea Pharmaceutica has been awarded USD 6 million by the Biomedical Advanced Research and Development Authority to continue development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Security & Safety, Switzerland
Tagged antibiotic development, antimicrobial resistance, ASPR, BARDA, Basilea Advances Antibiotic Pipeline with BARDA Funding for Oral Beta Lactam Combination Therapy, Basilea Pharmaceutica, Basilea Receives USD 6 Million BARDA Funding to Advance Development of Oral Antibiotic for Drug Resistant Urinary Infections, beta lactam beta lactamase inhibitor, ceftibuten ledaborbactam etzadroxil, complicated urinary tract infections cUTI, Cresemba®, David Veitch, FDA Fast Track designation, multidrug resistant bacteria, pyelonephritis, Qualified Infectious Disease Product QIDP, US Department of Health and Human Services, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has secured an extra USD 39 million from BARDA under its Other Transaction Agreement, bringing potential non-dilutive funding to USD 268 million over 12 years. This new tranche will finance the ongoing phase 3 trial of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Allschwil, antibacterial, antifungal, ASPR, BAL2062, BARDA, Basilea Pharmaceutica Ltd, Cresemba®, fosmanogepix, HHS, invasive candidiasis, invasive mold infections, multidrug-resistant Candida auris, orphan drug, Other Transaction Agreement, partnership, QIDP, Switzerland, Zevtera®
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?